论文部分内容阅读
目的探讨伊马替尼联合干扰素-α治疗慢性髓细胞性白血病的疗效。方法回顾性分析50例慢性髓细胞性白血病患者的临床资料,分为接受伊马替尼联合干扰素-α治疗的观察组(28例)和接受干扰素-α治疗的对照组(22例),观察治疗后缓解情况、不良反应例数以及生活质量。结果两组患者血液学缓解情况无明显差异,观察组细胞遗传学反应情况明显好于对照组,各类不良反应例数明显少于对照组,KPS评分、躯体功能、心理功能、社会功能、认知功能和总体生活质量评分明显高于对照组。结论伊马替尼联合干扰素-α能够改善治疗的细胞遗传学反应、减少不良反应例数、提高患者生活质量,是行之有效的治疗方式。
Objective To investigate the curative effect of imatinib combined with interferon-α on chronic myelogenous leukemia. Methods The clinical data of 50 patients with chronic myelogenous leukemia were retrospectively analyzed and divided into observation group (n = 28) and control group (n = 22) receiving imatinib combined with interferon- Observed after treatment, the number of adverse reactions and quality of life. Results There was no significant difference in hematological response between the two groups. The cytogenetic response in the observation group was significantly better than that in the control group. The number of adverse reactions in each group was significantly less than that in the control group. KPS score, physical function, psychological function, social function, Cognitive function and overall quality of life scores were significantly higher than the control group. Conclusions Imatinib combined with interferon-α can improve the cytogenetic response of treatment, reduce the number of adverse reactions and improve the quality of life of patients, which is an effective treatment.